Last Price$4.3(4.0%)
Market Cap$211.4B
EV/FCF LTM
(16.8x)
5Y avg
24.0x
Biotechnology industry
median
(0.6x)
Stock quality & Intrinsic value
6/10
(1.0%) overvalued
Silence Therapeutics plc EV/FCF LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| EV/FCF LTM | 0.0x | 165.5x | (9.1x) | (11.5x) |
Overvalued or undervalued?
Check the intrinsic value for SLN
and see if it's the right time to invest.
Silence Therapeutics plc (SLN) EV/FCF LTM comparison analysis
General
LTM EV/FCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Silence Therapeutics plcSLN
(3,782.8x)
45.7%
(6.7%)
(170.5%)
Median Peer Set
4.8x
18.9%
(47.6%)
0.4%
Incyte CorporationINCY
53.8x
14.8%
(94.0%)
0.8%
Novo Nordisk A/SNVO
42.3x
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc.REGN
16.1x
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
10.2x
23.6%
25.7%
41.5%
BioNTech SEBNTX
9.5x
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd.BGNE
(0.2x)
73.7%
(56.5%)
(35.9%)
Summit Therapeutics Inc.SMMT
(99.7x)
N/A
(68.7%)
N/A
Vertex Pharmaceuticals IncorporatedVRTX
(153.3x)
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
(702.4x)
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
SLN key stats
USD
GBP
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.3 0.0% | 0.9 217.9% | 3.6 287.2% | 8.1 125.8% | 4.1 (49.5%) | 2.7 (34.1%) | 3.7 35.5% | 1.1 (69.6%) | 0.3 (76.8%) | 0.2 (29.1%) | 0.0 (86.5%) | 0.0 (100.0%) | 1.0 0.0% | 0.0 (98.0%) | 0.0 (100.0%) | 0.3 0.0% | 7.0 2,158.4% | 17.1 142.7% | 21.7 26.8% | 31.6 45.7% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 9.7 | 12.4 | 7.9 | 9.0 | 5.4 | 5.4 | 8.8 | 14.6 | 10.9 | 11.8 | 10.2 | 13.0 | 0.0 | 4.8 | 10.3 | 13.5 | 12.8 |
% margin | 0.3 100.0% | 0.9 100.0% | 3.6 100.0% | (1.6) (19.7%) | (8.3) (203.8%) | (5.2) (194.4%) | (5.3) (146.0%) | (4.3) (384.3%) | (5.1) (1,972.4%) | (8.7) (4,727.4%) | (14.6) (59,126.7%) | (10.9) 0.0% | (10.8) (1,031.3%) | (10.2) (49,543.8%) | (13.0) 0.0% | 0.3 100.0% | 2.2 31.3% | 6.8 39.9% | 8.2 37.8% | 18.7 59.3% |
| Operating Expenses | 6.5 | 8.0 | 11.4 | 9.7 | 6.1 | 6.6 | 7.9 | 4.2 | 9.5 | 14.4 | 20.0 | 14.9 | 17.2 | 18.6 | 27.5 | 29.3 | 48.2 | 69.8 | 68.3 | 80.4 |
| Research & Development Expenses (R&D) | 3.1 | 3.0 | 5.9 | 9.7 | 12.4 | 7.9 | 9.0 | 5.4 | 5.4 | 8.8 | 14.6 | 10.9 | 11.8 | 10.2 | 13.0 | 17.0 | 25.9 | 42.3 | 44.0 | 54.7 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 5.0 | 5.6 | 10.0 | 6.1 | 5.0 | 7.9 | 4.2 | 4.1 | 5.5 | 5.4 | 4.1 | 5.4 | 8.3 | 14.5 | 12.3 | 18.0 | 27.5 | 24.3 | 25.7 |
% margin | (6.2) (2,118.2%) | (7.1) (765.8%) | (7.9) (219.2%) | (11.6) (143.0%) | (14.4) (352.7%) | (11.8) (438.4%) | (13.4) (365.9%) | (9.3) (833.7%) | (41.7) (16,143.6%) | (14.2) (7,753.8%) | (20.0) (80,846.7%) | (14.9) 0.0% | (16.1) (1,546.2%) | (18.5) (89,943.8%) | (27.5) 0.0% | (29.0) (9,317.2%) | (46.0) (654.3%) | (63.0) (369.0%) | (60.1) (277.7%) | (61.7) (195.5%) |
| Interest Income | 0.2 | 0.5 | 0.6 | 1.1 | 0.7 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.3 | 2.1 | 0.3 | 0.1 | 0.0 | 0.2 | 0.0 | 0.3 | 1.8 |
| Interest Expense | 0.1 | 0.0 | 0.0 | 0.0 | (0.1) | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | 0.0 | 0.1 | 0.0 |
| Pre-tax Income | (6.1) | (6.6) | (7.3) | (10.5) | (13.8) | (11.8) | (13.6) | (9.2) | (41.7) | (14.1) | (19.7) | (14.4) | (14.1) | (4.9) | (27.4) | (29.2) | (46.3) | (63.1) | (58.6) | (62.6) |
% effective tax rate | (0.6) 10.6% | (0.1) 1.4% | (0.2) 2.9% | (0.3) 2.6% | (0.7) 4.8% | (0.1) 0.5% | 0.2 (1.6%) | (0.1) 0.9% | (0.0) 0.1% | (0.1) 0.8% | (1.5) 7.4% | (4.3) 29.5% | (2.6) 18.5% | (2.8) 57.1% | (2.8) 10.3% | (4.2) 14.4% | (4.5) 9.7% | (8.9) 14.1% | (8.5) 14.5% | (8.8) 14.0% |
% margin | (5.4) (1,859.1%) | (6.5) (704.3%) | (7.0) (196.5%) | (10.2) (126.2%) | (13.8) (336.6%) | (11.7) (433.6%) | (13.6) (371.7%) | (9.2) (826.7%) | (41.7) (16,125.2%) | (14.1) (7,694.0%) | (18.3) (73,920.0%) | (10.2) 0.0% | (11.4) (1,096.1%) | (2.1) (10,112.5%) | (24.6) 0.0% | (25.0) (8,025.4%) | (41.8) (594.0%) | (54.2) (317.4%) | (50.1) (231.4%) | (53.8) (170.5%) |
| EPS | (34.04) | (16.07) | (11.11) | (13.19) | (17.23) | (13.03) | (7.33) | (2.95) | (6.51) | (0.95) | (1.09) | (0.47) | (0.49) | (0.09) | (1.05) | (1.00) | (1.53) | (1.83) | (1.56) | (1.45) |
| Diluted EPS | (34.04) | (16.07) | (11.11) | (13.19) | (17.23) | (13.03) | (7.33) | (2.95) | (6.51) | (0.95) | (1.09) | (0.47) | (0.49) | (0.09) | (1.05) | (1.00) | (1.53) | (1.83) | (1.56) | (1.45) |
% margin | (5.9) (2,011.3%) | (6.2) (671.5%) | (6.6) (184.2%) | (10.6) (131.4%) | (13.8) (336.8%) | (11.1) (413.1%) | (12.6) (345.3%) | (8.7) (780.8%) | (8.4) (3,255.8%) | (13.7) (7,500.0%) | (19.4) (78,633.3%) | (14.7) 0.0% | (15.7) (1,506.0%) | (4.3) (20,793.8%) | (26.9) 0.0% | (28.5) (9,161.9%) | (45.6) (648.5%) | (62.5) (365.9%) | (59.2) (273.6%) | (61.9) (196.2%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Silence Therapeutics plc's EV/FCF LTM?
As of today, Microsoft Corp's last 12-month EV/FCF LTM is (16.8x), based on the financial report for Sep 27, 2024 (Q3’2024). The average annual EV/FCF LTM for Silence Therapeutics plc have been 25.5x over the past three years, and 20.4x over the past five years.
2) Is Silence Therapeutics plc's EV/FCF LTM Good?
As of today, Silence Therapeutics plc's EV/FCF LTM is (16.8x), which is lower than industry median of (0.6x). It indicates that Silence Therapeutics plc's EV/FCF LTM is Good.